Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

This study is testing CAR-T cell therapy — a treatment that uses your own immune cells, genetically engineered to attack cancer — in people with blood cancers (lymphoma, myeloma, or leukemia) that have come back or stopped responding to standard treatments. **You may be eligible if...** - You have a confirmed blood cancer (lymphoma, myeloma, or leukemia) that has relapsed or is no longer responding to standard therapy - Your cancer cells test positive for specific surface proteins that the CAR-T cells are designed to target - You are in reasonably good health (ECOG 0–2) with adequate organ function - You are able to understand and sign the consent form **You may NOT be eligible if...** - You have a history of serious heart disease (heart failure class III/IV or ejection fraction below 50%) - You have a second, separate cancer - You have active HIV, Hepatitis B or C, or syphilis infection - You have an uncontrolled infection - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.